Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection

J Infect Dis. 2013 Oct 15;208(8):1231-9. doi: 10.1093/infdis/jit322. Epub 2013 Jul 21.

Abstract

The contribution of host T-cell immunity and HLA class I alleles to the control of human immunodeficiency virus (HIV-1) replication in natural infection is widely recognized. We assessed whether vaccine-induced T-cell immunity, or expression of certain HLA alleles, impacted HIV-1 control after infection in the Step MRKAd5/HIV-1 gag/pol/nef study. Vaccine-induced T cells were associated with reduced plasma viremia, with subjects targeting ≥3 gag peptides presenting with half-log lower mean viral loads than subjects without Gag responses. This effect was stronger in participants infected proximal to vaccination and was independent of our observed association of HLA-B*27, -B*57 and -B*58:01 alleles with lower HIV-1 viremia. These findings support the ability of vaccine-induced T-cell responses to influence postinfection outcome and provide a rationale for the generation of T-cell responses by vaccination to reduce viremia if protection from acquisition is not achieved. Clinical trials identifier: NCT00095576.

Keywords: Gag-specific T cells; HIV-1 vaccine; HLA class I alleles; Step study.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Intramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS Vaccines / administration & dosage*
  • AIDS Vaccines / immunology
  • Adult
  • Alleles
  • Double-Blind Method
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • HIV-1 / immunology*
  • HLA Antigens / biosynthesis
  • HLA Antigens / genetics
  • HLA Antigens / immunology
  • Histocompatibility Antigens Class I / immunology
  • Humans
  • Male
  • RNA, Viral / genetics
  • T-Lymphocytes / immunology*
  • Viral Load / immunology
  • Viremia / blood
  • Viremia / immunology
  • Viremia / prevention & control*
  • gag Gene Products, Human Immunodeficiency Virus / immunology*

Substances

  • AIDS Vaccines
  • HLA Antigens
  • Histocompatibility Antigens Class I
  • RNA, Viral
  • gag Gene Products, Human Immunodeficiency Virus

Associated data

  • ClinicalTrials.gov/NCT00095576